PharmaTimesNews & Politicsnews

Oblenio doses first patients in phase 1a autoimmune trial

Wednesday, August 5, 2026John PinchingView original

Study evaluates tri‑specific T cell engager LBL‑051

Read the full article on the original site.

Read Full Article